Factors Influencing a Specific Pathologic Diagnosis of Non-Small-Cell Lung Carcinoma

被引:6
|
作者
Sulpher, Jeffrey A. [1 ]
Owen, Scott P. [2 ]
Hon, Henrique [2 ]
Tobros, Kimberly [2 ]
Shepherd, Frances A. [2 ]
Sabri, Elham [3 ]
Gomes, Marcio [4 ]
Sekhon, Harman [4 ]
Liu, Geoffrey [2 ]
Canil, Christina M. [1 ]
Wheatley-Price, Paul [1 ]
机构
[1] Univ Ottawa, Dept Med, Ottawa Hosp, Ctr Canc, Ottawa, ON, Canada
[2] Univ Toronto, Univ Hlth Network, Princess Margaret Hosp, Div Med Oncol & Hematol,Dept Med, Toronto, ON M5S 1A1, Canada
[3] Univ Ottawa, Res Inst, Ottawa Hosp, Ottawa, ON, Canada
[4] Univ Ottawa, Dept Pathol & Lab Med, Ottawa Hosp, Ottawa, ON, Canada
关键词
Chart review; Diagnosis; Histology; Non-small-cell lung cancer; CANCER; CHEMOTHERAPY; MUTATIONS; GEFITINIB; CYTOLOGY; EGFR; ADENOCARCINOMA; CLASSIFICATION; CARBOPLATIN; PACLITAXEL;
D O I
10.1016/j.cllc.2012.11.004
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Pathologic subtyping of non-small-cell lung carcinoma is increasingly important when selecting therapy. The records of 739 patients were reviewed to identify factors associated with attaining a specific pathologic diagnosis. Only 456 (62%) of patients received a specific pathologic diagnosis, which was significantly associated with histologic biopsy samples, immunohistochemical testing, and diagnosis outside of an academic center. Introduction: Historically, a non-small-cell lung carcinoma diagnosis, without pathologic subclassification, provided sufficient information to guide therapy. Evidence now demonstrates that pathologic subtype classification is central in selecting optimal treatment. This review aimed to identify factors associated with a specific pathologic diagnosis. Methods: All nonoperative cases of non-small-cell lung carcinoma (NSCLC) referred to the medical oncology divisions of the Ottawa Hospital Cancer Centre (2008) and Princess Margaret Hospital, Toronto (2007-2010) were identified. The charts were reviewed for demographics, diagnostic methods, and final diagnosis. Logistic regression was performed to identify variables associated with a specific diagnosis. Results: Of 739 patient records analyzed, 377 (51%) were men, 299 (40%) were aged over 70 years, and 510 (69%) had an Eastern Cooperative Oncology Group performance status of 0-2. Three hundred and eighty five (52%) of patients were diagnosed in a tertiary academic center. The lung primary was sampled in 503 (68%) of patients. Computed tomography-guided biopsy (n = 370, 50%) and bronchoscopy (n = 179, 24%) were the most common techniques. Four hundred and seventy seven (65%) of biopsies were cytologic specimens alone, and immunohistochemistry was performed in 337 (46%) of cases. The most common diagnoses were adenocarcinoma (n = 338, 46%), NSCLC not otherwise specified (n = 254, 34%), and squamous cell carcinoma (n = 115, 16%). Overall, 456 (62%) of patients received a specific pathologic diagnosis. Factors significantly associated with attaining a specific pathologic diagnosis were diagnosis outside an academic center (adjusted odds ratios [OR] 2.1 [95% CI, 1.41-3.14]; P = .0003), histologic laboratory samples (adjusted OR 1.58 [95% CI, 1.003-2.49]; P = .049), and immunohistochemical testing (adjusted OR 1.82 [95% CI, 1.25-2.70], P = .0021). Conclusions: A significant minority of patients with NSCLC do not receive a specific pathologic diagnosis. In an era of individualized medicine, this may potentially impact optimal clinical management. Clinical Lung Cancer, Vol. 14, No. 3, 238-44 (C) 2013 Elsevier Inc. All rights reserved.
引用
收藏
页码:238 / 244
页数:7
相关论文
共 50 条
  • [42] CHRONIC ORAL ETOPOSIDE IN NON-SMALL-CELL LUNG-CARCINOMA
    ESTAPE, J
    PALOMBO, H
    SANCHEZLLORET, J
    AGUSTI, C
    GRAU, JJ
    DANIELS, M
    VINOLAS, N
    SOLA, C
    BIETE, A
    RAMIREZ, J
    EUROPEAN JOURNAL OF CANCER, 1992, 28A (4-5) : 835 - 837
  • [43] Precision Diagnosis and Treatment for Advanced Non-Small-Cell Lung Cancer
    Reck, Martin
    Rabe, Klaus F.
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (09): : 849 - 861
  • [44] Non-small-cell lung carcinoma: role of the Notch signaling pathway
    Barse, Levi
    Bocchetta, Maurizio
    LUNG CANCER-TARGETS AND THERAPY, 2015, 6 : 43 - 53
  • [45] MET: a new promising biomarker in non-small-cell lung carcinoma
    Perez-Ramirez, Cristina
    Canadas-Garre, Marisa
    Jimenez-Varo, Enrique
    Jose Faus-Dader, Maria
    Angel Calleja-Hernandez, Miguel
    PHARMACOGENOMICS, 2015, 16 (06) : 631 - 647
  • [46] CHEMOTHERAPY OUTCOMES IN ADVANCED NON-SMALL-CELL LUNG-CARCINOMA
    LIU, RJ
    SEMINARS IN ONCOLOGY, 1993, 20 (04) : 296 - 301
  • [47] Evaluation of nintedanib in patients with non-small-cell lung carcinoma (NSCLC)
    Casas Hidalgo, Inmaculada
    Valle Corpas, Margarita
    Casas Hidalgo, Maria de la Paz
    Moreno Raya, Patricia
    Rodriguez Delgado, Alejandro
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2017, 39 (01) : 324 - 324
  • [48] Immunotherapy in Non-Small-Cell Lung Carcinoma: From Inflammation to Vaccination
    Van den Heuvel, Michel M.
    Burgers, Sjaak A.
    van Zandwijk, Nico
    CLINICAL LUNG CANCER, 2009, 10 (02) : 99 - 105
  • [49] Therapeutic potentials of curcumin in the treatment of non-small-cell lung carcinoma
    Salehi, Mahsa
    Movahedpour, Ahmad
    Tayarani, Alireza
    Shabaninejad, Zahra
    Pourhanifeh, Mohammad H.
    Mortezapour, Erfan
    Nickdasti, Ali
    Mottaghi, Reza
    Davoodabadi, Abdolhossein
    Khan, Haroon
    Savardashtaki, Amir
    Mirzaei, Hamed
    PHYTOTHERAPY RESEARCH, 2020, 34 (10) : 2557 - 2576
  • [50] Percutaneous implantation of non-small-cell lung carcinoma: Technique and observations
    Hamide, JP
    Qian, Z
    Diethelm, L
    Skrepnik, N
    CastanedaZuniga, WR
    Hunt, JD
    ACADEMIC RADIOLOGY, 1997, 4 (09) : 629 - 633